In our current study, we found that icotinib-containing treatment was able to suppress activities of EGFR, MAPK, and Akt proteins; it was not total inhibition of protein phosphorylation, but reduction of tumor xenograft volume, and size may not be through suppression of these protein activities. The gene discussed is EGFR; the disease is neoplasm.